These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28651304)

  • 21. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
    Reiberger T; Ferlitsch A; Payer BA; Pinter M; Homoncik M; Peck-Radosavljevic M;
    J Gastroenterol; 2012 May; 47(5):561-8. PubMed ID: 22170417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.
    González-Abraldes J; Albillos A; Bañares R; Del Arbol LR; Moitinho E; Rodríguez C; González M; Escorsell A; García-Pagán JC; Bosch J
    Gastroenterology; 2001 Aug; 121(2):382-8. PubMed ID: 11487547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients.
    Castaño G; Viudez P; Riccitelli M; Sookoian S
    Ann Hepatol; 2003; 2(1):36-40. PubMed ID: 15094704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carvedilol or propranolol in portal hypertension? A randomized comparison.
    Hobolth L; Møller S; Grønbæk H; Roelsgaard K; Bendtsen F; Feldager Hansen E
    Scand J Gastroenterol; 2012 Apr; 47(4):467-74. PubMed ID: 22401315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics.
    De BK; Das D; Sen S; Biswas PK; Mandal SK; Majumdar D; Maity AK
    J Gastroenterol Hepatol; 2002 Feb; 17(2):183-9. PubMed ID: 11966949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J
    Lancet; 2019 Apr; 393(10181):1597-1608. PubMed ID: 30910320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial.
    Gupta N; Kumar A; Sharma P; Garg V; Sharma BC; Sarin SK
    Liver Int; 2013 Sep; 33(8):1148-57. PubMed ID: 23601333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
    La Mura V; Abraldes JG; Raffa S; Retto O; Berzigotti A; García-Pagán JC; Bosch J
    J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.
    Villanueva C; Albillos A; Genescà J; Abraldes JG; Calleja JL; Aracil C; Bañares R; Morillas R; Poca M; Peñas B; Augustin S; Garcia-Pagan JC; Pavel O; Bosch J
    Hepatology; 2016 Jan; 63(1):197-206. PubMed ID: 26422126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial.
    Kimer N; Pedersen JS; Busk TM; Gluud LL; Hobolth L; Krag A; Møller S; Bendtsen F;
    Hepatology; 2017 Feb; 65(2):592-603. PubMed ID: 27775818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
    Manolakopoulos S; Triantos C; Theodoropoulos J; Vlachogiannakos J; Kougioumtzan A; Papatheodoridis G; Tzourmakliotis D; Karamanolis D; Burroughs AK; Archimandritis A; Raptis S; Avgerinos A
    J Hepatol; 2009 Sep; 51(3):468-74. PubMed ID: 19616339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study.
    Tandon P; Moncrief K; Madsen K; Arrieta MC; Owen RJ; Bain VG; Wong WW; Ma MM
    Liver Int; 2009 Aug; 29(7):1110-5. PubMed ID: 19490420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis.
    Schiedermaier P; Koch L; Stoffel-Wagner B; Layer G; Sauerbruch T
    Aliment Pharmacol Ther; 2003 Oct; 18(8):777-84. PubMed ID: 14535870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PORTAL HYPERTENSION TREATMENT WITH CANDESARTAN PLUS PROPRANOLOL FOR NINE MONTHS RESTORES NORMAL PORTAL CIRCULATION HEMODYNAMIC PATTERN.
    Abd Alla MD; Eid EMM; Soliman AIA; Elhawary MA; Kilany YF; Abd-Almonaem G; Bayoumi SS; Moursy MRA; Al-Zaem FAM
    J Egypt Soc Parasitol; 2016 Dec; 46(3):587-604. PubMed ID: 30230756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
    Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
    J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic prevention of variceal bleeding and rebleeding.
    Baiges A; Hernández-Gea V; Bosch J
    Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Propranolol Reduces Portal Vein Diameter in Schistosomal Liver Disease with Portal Hypertension: A Prospective Cohort Study.
    Sinkala E; Vinikoor M; Zyambo K; Besa E; Nsokolo B; Kelly P
    Am J Trop Med Hyg; 2020 Apr; 102(4):832-837. PubMed ID: 32067625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.
    Abraldes JG; Tarantino I; Turnes J; Garcia-Pagan JC; Rodés J; Bosch J
    Hepatology; 2003 Apr; 37(4):902-8. PubMed ID: 12668985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis.
    Reverter E; Lozano JJ; Alonso C; Berzigotti A; Seijo S; Turon F; Baiges A; Martínez-Chantar ML; Mato JM; Martínez-Arranz I; La Mura V; Hernández-Gea V; Bosch J; García-Pagán JC
    Liver Int; 2019 Apr; 39(4):705-713. PubMed ID: 30637923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.